Fibroblast Growth Factor 23 (FGF-23) is an important molecule for clinical, dialysis and transplant nephrology - Basic review of current status of knowledge;Fibroblastový růstový faktor 23 (FGF-23, Fibroblast Growth Factor) je molekulou s velkým významem pro klinickou, dialyzační i transplantační nefrologii - Základní přehled současných poznatků

Aktuality v Nefrologii

Volumn 17, Issue 1, 2011, Pages 17-22

  Sulková, Sylvie Dusilová ^a,b   Kalousová, Marta ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic kidney disease; Enzyme CYP27B1; Fibroblast growth factor 23; Klotho; Parathyroid hormone; Phosphate

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE;

BONE CELL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIET THERAPY; DISEASE MARKER; ENZYME BLOOD LEVEL; HYPERTHYROIDISM; PARATHYROID FUNCTION; PARATHYROID GLAND; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; REVIEW;

EID: 79955435042     PISSN: 1210955X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Canziani MEF, Tomiyama C, Higa A: Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011; 31: 26-32.
2. Drueke TB: Klotho, FGF-23 and FGF receptor in chronic kidney disease: a yin-yang situation? Kidney Int 2010; 78: 1057-1060.
3. Damasiewicz M, Toussaint ND, Polkinghorne KR: Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications. Nephrology (Carlton) 2011; 16: 261-268.
4. Evenepoel P, Meijers B, Viaene L et al: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigma for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276.
5. Fliser D, Kollerits B, NEyer U et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007; 18: 2601-2608. (Pubitemid 47378877)
6. Galitzer H, Ben-Dow IZ, Silver J: Parathyroid cell resistence to fibroblast growth factor in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218.
7. Guttierez O, Isakova T, Rhee E et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
8. Guttierez OM,Mannstadt M, Isakova T et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
9. Ix JH, Shlipak MG, Wassel CL et al: Fibroblast growth factor-23 and early decrements in kidney functions: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997.
10. Imanishi Y, Inaba M, Nakatsuka K et al: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946.
11. Imel EA, Econs MJ: Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 2005; 16: 2565-2575.
12. Isakova T. Gutierrez O, Wolf M: A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009; 76: 705-716.
13. Isakowa T, Wolf MS: FGF-23 or PTH: which comes first in CKD? Kidney Int 2010; 78: 947-949.
14. Jean G, Terrat JC, Vanel T et al: High levels of serum fibroblast growth factor FGF-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796.
15. Komaba H, Fugakawa M: FGF-23 parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77: 292-298.
16. Liu S, Quarles LD: How fibroblast growth factor works. J Am Soc Nephrol 2007; 18: 1637-1647. (Pubitemid 46870300)
17. Kanaan N, Claes K, Devogelaer JP et al: Fibroblast growth factor 23 and parathyroid hormone are associated with posttransplant bone mineral density loss. Clin J Am Soc Nephrol 2010; 5: 1887-1992.
18. Kanbay N, Nicoleta N, Selcoki Y et al: Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in chronic kidney disease patients. Clin J Am Soc Nephrol 2010; 5: 1780-1786.
19. Kazam JJ, Sato F, Omori K et al: Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125. (Pubitemid 41623338)
20. Kuro-o M: Klotho in chronic kidney disease - what's new? Nephrol Dial Transplant 2009; 24: 1705-1708.
21. Lafage-Proust MH: Does down-regulation of the FGF-23 signaling pathway in hyperplastic parathyroid glanc contribute to refractedy secondary hyperparathyroidism in CKD patients? Kidney Int 2010; 77: 390-392.
22. Mirams M, Robinson BG, Mason RS et al: Bone as a source of FGF-23: regulativ by phosphate? Bone 2004; 35: 1192-1199.
23. Martin KJ, Gonzalez EA: Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, hen to start and how to treat. Clin J Am Soc Nephrol 2011; 6: 440-446.
24. Moe SM, Drueke TB, Cunningham J et al: Definition, evaluation and classification of renal osteodysstrophy. A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
25. Nakai K, Komaba H, Fugakawa M: New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010; 23: 619-625.
26. Nakanishi S, Kazama JJ, Nu-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refraktory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178. (Pubitemid 41623344)
27. Nitta K. Relationship between fibroblast growth factor-23 and mineral metabolism in chronic kidney disease. Int J Nephrol 2010; doi:10.4061/2010/ 167984.
28. Oliveira RB, Cancela ALE, Graciolli FG et al: Early kontrol of PTH and FGF-23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
29. Peiskerová M, Kalousová M, Kratochvílová M et al: Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res 2009; 32: 267-283.
30. Serra AL, Wuhrmann C, Withrich RP et al: Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008; 52: 1151-1157.
31. Shroff R, Shanahan CM: Klotho: an elixír of youth for the vasculature? J Am Soc Nephrol 2011; 22: 5-7.
32. Trombetti A, Richert L, Graf JD et al: Early Post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011 Feb 18 (Epub ahead of print).
33. Vervloet MG, van Ittersum FJ, Buttler RM: Effects of dietary phosphate and calcium intake on fibroblast grott factor 23. CJASN 2011; doi:10.2215/CJN.04730510.
34. Wetmore JB, Liu S, Krebill R et al: Effects of cinacalcet and concurrent low-dose vitamin D on FGF-23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116.
35. Zoccali C: FGF-23 in dialysis patients: ready for prime time? Nephrol Dial Transplant 2009; doi:10.1093/ndt/gfn688.